Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.7 |
mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | DBeQ | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |